In patients with essential hypertension and signs of left ventricular hypertrophy (LVH), is losartan-based therapy more effective than atenolol-based therapy?
D e s i g n
Randomized (unclear allocation concealment*), blinded (patients and monitoring committee),* controlled trial with ≥ 4 years follow-up.
S e t t i n g
Multicenter trial in Europe and the United States.
P a t i e n t s
9222 patients 55 to 80 years of age (mean age 67 y, 54% women) with hypertension (sitting blood pressure [BP] after 1 to 2 wk of placebo of 160 to 200 mm Hg systolic, 95 to 115 mm Hg diastolic, or both) and electrocardiographic signs of LVH. Exclusion criteria included secondary hypertension; myocardial infarction (MI) or stroke within the previous 6 months; angina pectoris requiring treatment with β-blockers or calcium antagonists; and heart failure or left ventricular ejection fraction ≤ 40%. Follow-up was 99%.
I n t e r v e n t i o n
Patients were allocated to losartan-based therapy (n = 4605) or atenolol-based therapy (n = 4588). Losartan and atenolol were started at 50 mg/d, combined with low-dose hydrochlorothiazide if needed and then increased to 100 mg/d if needed, and supplemented with other antihypertensive drugs (except β-blockers, angiotensin-converting enzyme [ACE] inhibitors, or angiotensinreceptor blockers [ARBs]) to reach a target BP < 140/90 mm Hg.
M a i n o u t c o m e m e a s u r e s
The primary end point was a composite of cardiovascular mortality, MI, and stroke. One of the secondary end points was newonset diabetes.
M a i n r e s u l t s
Analysis was by intention to treat. The composite end point, fatal or nonfatal stroke and new-onset diabetes, occurred less frequently in patients assigned to losartan than in those assigned to atenolol (Table) . No difference existed between the groups for cardiovascular mortality or MI. BP control, dose titration, and use of other antihypertensives were similar in both groups.
C o n c l u s i o n
In patients with essential hypertension and signs of left ventricular hypertrophy, losartan reduced strokes and new-onset diabetes more than atenolol. 
C o m m e n t a r y
Physicians can become frustrated when prescribing medications for asymptomatic patients with chronic diseases. They may doubt that the benefit of treatment exceeds the cost and risks for side effects. Patients may not comply if the cost or side effects exceed perceived benefits. As a result, therapeutic goals may be difficult to achieve. The LIFE studies show that potentially life-threatening complications can be reduced with fewer side effects. The original, placebo-controlled public health trials of hypertension used thiazides and β-blockers. These agents successfully reduced cardiovascular disease and stroke; thus, they have been considered first-line therapy for hypertension (1). In the LIFE studies, losartan reduced stroke and combined cardiovascular end points to a greater degree than atenolol. The data indicate that cardiovascular protection by using an ARB is superior to that of a β-blocker for patients with hypertension and LVH, which are independent risk factors for cardiovascular disease. Other trials using ACE inhibitors and ARBs have shown cardiovascular and renal benefits unrelated to their effects on hypertension (2, 3). We need to reconsider the selection of first-line hypertensive therapy, particularly in patients at high risk.
Several comments should be made concerning the study methodology and results. Most patients required ≥ 2 agents to reach target-level BP, which is consistent with other trials (4 
Q u e s t i o n
In patients with diabetes, essential hypertension, and signs of left ventricular hypertrophy (LVH), is losartan-based therapy more effective than atenolol-based therapy?
D e s i g n Randomized (unclear allocation concealment*), blinded (patients and monitoring committee),* controlled trial with ≥ 4 years follow-up.
S e t t i n g
P a t i e n t s
1195 patients (a predefined subgroup of patients who had diabetes mellitus at the start of the LIFE study) who were 55 to 80 years of age (mean age 67 y, 53% women) with hypertension (sitting blood pressure [BP] after 1 to 2 wk of placebo of 160 to 200 mm Hg systolic, 95 to 115 mm Hg diastolic, or both) and electrocardiographic signs of LVH. Exclusion criteria included secondary hypertension; myocardial infarction (MI) or stroke within the previous 6 months; angina pectoris requiring treatment with β-blockers or calcium antagonists; and heart failure or left ventricular ejection fraction ≤ 40%. Followup was 100%.
I n t e r v e n t i o n
Patients were allocated to losartan-based therapy (n = 586) or atenolol-based therapy (n = 609). Losartan and atenolol were started at 50 mg/d, combined with low-dose hydrochlorothiazide if needed then increased to 100 mg/d if needed, and supplemented with other antihypertensives (except β-blockers, angiotensin-converting enzyme [ACE] inhibitors, or angiotensin-receptor blockers [ARBs]) to reach a target BP < 140/90 mm Hg.
M a i n o u t c o m e m e a s u r e s
The primary end point was a composite of cardiovascular mortality, MI, and stroke. One of the secondary end points was heart failure.
M a i n r e s u l t s
Analysis was by intention to treat. The composite end point, cardiovascular mortality, allcause mortality, and heart failure, occurred less frequently in patients assigned to losartan than in those assigned to atenolol (Table) .
C o n c l u s i o n
In patients with diabetes, essential hypertension, and signs of left ventricular hypertrophy, losartan reduced cardiovascular morbidity and mortality and all-cause mortality more than atenolol. C o m m e n t a r y (continued from page 86) 25 years ago, patients with diabetic nephropathy had little hope of averting dialysis. Risk can now be substantially decreased with better glucose control, reduction in BP to normotensive levels, and treatment with an ACE inhibitor or ARB.
The LIFE studies concluded that losartan mildly reduced cardiovascular complications more than atenolol. The reduction in side effects with ARBs was a positive step toward increasing patient satisfaction and compliance. Fewer side effects should result in greater adherence. Public programs should advertise that antihypertensive therapy is attainable with fewer unpleasant side effects.
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